Shortly after acquiring Elektrofi to beef up its subcutaneous drug-delivery offerings, Halozyme Therapeutics has struck ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

Halozyme Therapeutics’ HALO shares climbed nearly 4%, following the release of preliminary full-year 2025 results on Jan. 28, ...

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

Subcutaneous fat is stored just beneath the skin and can be pinched with your fingers. Visceral fat lies deep within the abdominal walls and surrounds the organs. Visceral fat tends to cause bad ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.